Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SimpliGraft
- Development stage
- Unknown
- Lead developer
- Xtant Medical
- Administration
- Topical
01
Overview
SimpliGraft is a hydrated human tissue allograft developed by Xtant Medical for the treatment of chronic and acute wounds. It is derived from human skin and processed to retain the natural extracellular matrix (ECM) and endogenous growth factors, providing a biological scaffold that supports cellular infiltration and tissue regeneration. The product is designed for ease of use in clinical settings, requiring no rehydration, and is typically used in the management of diabetic foot ulcers, venous leg ulcers, and surgical wounds. Xtant Medical entered into a distribution agreement with SeaSpine (now Orthofix) to market the product in the United States.
- Brand names
- SimpliGraft
- Other names
- SimpliGraft Hydrated Allograft
Beyond the preview
Go deeper on SimpliGraft.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SimpliGraft.